A 32-year-old man from rural Uttar Pradesh presents with a 3-week history of bloody diarrhea, abdominal pain, and weight loss. Stool microscopy reveals trophozoites with ingested RBCs. Serology is negative. All of the following statements about his infection are correct EXCEPT:

Explanation

## Management of Entamoeba histolytica Infection ### Clinical Context: Acute Invasive Intestinal Disease This patient has acute amoebic dysentery with: - Bloody diarrhea and trophozoites in stool - RBC-containing trophozoites (pathognomonic for tissue invasion) - Negative serology (typical in acute intestinal disease; serology becomes positive in extraintestinal disease) ### Treatment Algorithm for E. histolytica | Infection Type | Treatment | |---|---| | Invasive intestinal / extraintestinal | Tissue amebicide (Metronidazole 750 mg TDS × 7–10 days) **followed by** luminal agent | | Asymptomatic cyst carrier | Luminal agent only (Paromomycin or Iodoquinol) | ### Why Option C is the EXCEPT Answer **Key Point:** Option C states that "asymptomatic cyst carriers **require** treatment with a luminal agent **regardless of serology status**." This is incorrect on two grounds: 1. **Asymptomatic cyst carriers in endemic areas do NOT universally require treatment.** Per WHO guidelines and standard references (Harrison's Principles of Internal Medicine, 21st ed.; Mandell's Principles of Infectious Diseases), treatment of asymptomatic carriers is **not** universally recommended in endemic regions due to high reinfection rates, cost-benefit considerations, and potential for spontaneous clearance. Treatment is generally reserved for symptomatic patients, immunocompromised individuals, and travelers returning to non-endemic areas. 2. **The "regardless of serology status" qualifier is misleading.** Serology is not the primary determinant of whether an asymptomatic carrier should be treated; the decision is based on clinical status, immune status, and epidemiological context. Thus, the statement as written is factually incorrect — asymptomatic carriers do **not** universally require treatment. ### Why the Other Options Are Correct **Option A (RBC-containing trophozoites indicate invasion):** Trophozoites that have ingested RBCs (erythrophagocytosis) are pathognomonic for *E. histolytica* tissue invasion and mucosal ulceration. This distinguishes pathogenic *E. histolytica* from non-pathogenic *E. dispar* (KD Tripathi, Essentials of Medical Pharmacology, 8th ed.). **Option B (Metronidazole first-line):** Metronidazole 750 mg TDS × 7–10 days is the first-line tissue amebicide for invasive intestinal and extraintestinal amoebiasis. It is highly effective against trophozoites in tissues and the intestinal wall (Harrison's, 21st ed.). **Option D (Negative serology in acute intestinal disease):** Serology (IgG antibodies) is negative in early/acute intestinal infection because antibodies take 1–2 weeks to develop and may not rise significantly in purely luminal disease. Serology becomes positive in 90–95% of patients with extraintestinal disease (e.g., liver abscess). Negative serology in a patient with dysentery is therefore consistent with acute intestinal infection rather than extraintestinal disease (Mandell's Principles of Infectious Diseases, 9th ed.). ### Clinical Pearl **High-Yield:** Always use a two-drug regimen for invasive disease: 1. **Tissue amebicide** (metronidazole) → kills trophozoites in tissue 2. **Luminal agent** (paromomycin, iodoquinol) → clears cysts from the intestinal lumen Failure to give a luminal agent after metronidazole can result in relapse from residual cysts. **Mnemonic:** **TISSUE then LUMEN** — treat the invasive form first, then eradicate the intestinal reservoir.